<DOC>
	<DOCNO>NCT00023868</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , fluorouracil , leucovorin , work different way stop growth cancer cell , either kill cell stop cell divide . Chemoembolization kill tumor cell block blood flow tumor keep chemotherapy drug near tumor . It yet know chemoembolization effective standard chemotherapy treat metastatic cancer . PURPOSE : This phase I trial randomize phase III trial study effectiveness chemoembolization treat patient colorectal cancer metastatic liver .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Chemoembolization Treating Patients With Colorectal Cancer Metastatic Liver</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival patient liver-dominant metastatic colorectal adenocarcinoma treat irinotecan , fluorouracil , leucovorin calcium without hepatic chemoembolization . - Compare response liver , time hepatic tumor progression , time extrahepatic tumor progression patient treat regimen . - Compare possible treatment difference respect morbidity , toxic effect chemoembolization , toxic effect chemotherapy , death cancer-related complication patient . OUTLINE : This phase I dose-escalation study follow phase III randomize , multicenter study . ( Phase I close 10/14/02 . ) - Phase I : Patients phase I sequentially enrol 1 3 treatment regimen . ( Phase I close 10/14/02 . ) - Regimen A : Patients receive irinotecan IV 60-90 minute , leucovorin calcium IV , fluorouracil IV 10 minute day 1 , 8 , 15 , 22 . Patients undergo hepatic embolization embolic suspension day 36 . - Regimen B : Patients receive chemotherapy regimen A . Patients undergo hepatic chemoembolization lower-dose cisplatin , doxorubicin , mitomycin day 36 . - Regimen C : Patients receive chemotherapy regimen A . Patients undergo hepatic chemoembolization higher-dose cisplatin , doxorubicin , mitomycin day 36 . After 1 week rest , patient regimens receive second 4-week course systemic chemotherapy . Cohorts 3-10 patient sequentially enrol maximum tolerate dose ( MTD ) chemotherapy chemoembolization determine . The MTD define dose precede least 4 10 patient experience dose-limiting toxicity . - Phase III : Patients stratify accord liver volume involvement ( le 25 % vs 25-50 % vs 50 % le 75 % ) participating center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive irinotecan IV 60-90 minute , leucovorin calcium IV , fluorouracil IV 10 minute day 1 , 8 , 15 , 22 . Courses repeat every 6 week absence disease progression . - Arm II : Patients receive chemotherapy arm I . Patients undergo hepatic chemoembolization cisplatin , doxorubicin , mitomycin day 36 . Chemotherapy repeat every 6 week absence disease progression . Chemoembolization may repeat every 6 week 2-4 course necessary . Patients phase III follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 9-18 patient accrued phase I study . ( Phase I close accrual 10/14/02 . ) Approximately 315 patient accrued phase III study within 2.5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic colorectal adenocarcinoma Measurable metastasis liver least 1.0 cm Less 75 % total liver volume Known extrahepatic disease limit lymph node le 2 cm No ascites Ineligible surgery PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 2,000/mm^3 Platelet count least 90,000/mm^3 No bleed diathesis correctable standard therapy Hepatic : Ineligible follow criterion concurrently present : High risk hepatic failure ( 50 % liver involvement tumor ) Bilirubin great 2.0 mg/dL SGOT great 100 U/L Lactate dehydrogenase great 425 U/L No hepatic encephalopathy No portal vein occlusion without hepatopedal collateral flow demonstrate angiography No portal hypertension hepatofugal flow Renal : Creatinine great 2.0 mg/dL Cardiovascular : No myocardial infarction within past 6 month No evidence congestive heart failure No severe peripheral vascular disease would preclude catheterization Other : No severe allergy intolerance contrast medium , narcotic , sedative , atropine No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior adjuvant immunotherapy regimen colon cancer Chemotherapy : At least 6 month since prior adjuvant chemotherapy recover No 1 prior adjuvant chemotherapy regimen colon cancer No prior hepatic arterial infusion chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 1 month since prior radiotherapy No prior hepatic radiotherapy Surgery : At least 1 month since prior surgery Prior surgical resection ablation liver metastasis allow Other : No concurrent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>liver metastasis</keyword>
</DOC>